Late stage cell therapy developer Cytori Therapeutics, a company creating autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently published its findings from a 12-month clinical follow-up of scleroderma patients who were enrolled in the Scleradec-I clinical trial on hand dysfunction associated with the disease. The Scleradec-I study, an investigator-initiated, open-label 12 patient trial, was led by Dr. Brigitte Granel and Dr. Guy Magalon from the Assistance Publique des Hôpitaux de Marseille. The manuscript, titled, “Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up” was published in the journal Rheumatology.
Learn about the benefits of Cytori’s cell therapy here: http://bit.ly/1Slm3yc